Journal article icon

Journal article

A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol

Abstract:

Background BRCA1 and BRCA2 genes are critical in homologous recombination DNA repair and have been implicated in familial breast and ovarian cancer tumorigenesis. Tumour cells with these mutations demonstrate increased sensitivity to cisplatin and poly (ADP-ribose) polymerase (PARP) inhibitors. 6MP was identified in a screen for novel drugs and found to selectively kill BRCA-defective cells in a xenograft model as effectively as the PARP inhibitor AGO14699, even after thes...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1186/1471-2407-14-983

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Role:
Author
Cancer Research UK More from this funder
National Institute for Health Research Oxford Biomedical Research Centre More from this funder
Publisher:
BioMed Central Publisher's website
Journal:
BMC Cancer Journal website
Volume:
14
Issue:
1
Article number:
983
Publication date:
2014-12-19
Acceptance date:
2014-12-11
DOI:
EISSN:
1471-2407
ISSN:
1471-2407
Language:
English
Keywords:
Pubs id:
pubs:503518
UUID:
uuid:cabbb22f-00ba-4def-a418-9e7b8e8c5c0f
Local pid:
pubs:503518
Source identifiers:
503518
Deposit date:
2015-11-03

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP